These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 20843312)
1. "Show me the money": a fair criticism of economic studies on inhaled bronchodilators for COPD. Kostikas K; Bouros D BMC Pulm Med; 2010 Sep; 10():48. PubMed ID: 20843312 [TBL] [Abstract][Full Text] [Related]
2. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM Value Health; 2005; 8(1):32-46. PubMed ID: 15841892 [TBL] [Abstract][Full Text] [Related]
3. Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions. Neyt M; Devriese S; Thiry N; Van den Bruel A BMC Pulm Med; 2010 Sep; 10():47. PubMed ID: 20843311 [TBL] [Abstract][Full Text] [Related]
4. [Economic value of tiotropium in the treatment of chronic obstructive pulmonary disease]. Schramm W; Haake D; Brandt A Praxis (Bern 1994); 2005 Nov; 94(46):1803-10. PubMed ID: 16329401 [TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Nielsen R; Kankaanranta H; Bjermer L; Lange P; Arnetorp S; Hedegaard M; Stenling A; Mittmann N Respir Med; 2013 Nov; 107(11):1709-21. PubMed ID: 23856511 [TBL] [Abstract][Full Text] [Related]
6. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Keam SJ; Keating GM Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163 [TBL] [Abstract][Full Text] [Related]
7. Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore. Lee KH; Phua J; Lim TK Respir Med; 2006 Dec; 100(12):2190-6. PubMed ID: 16635566 [TBL] [Abstract][Full Text] [Related]
8. Which long-acting bronchodilator is most cost-effective for the treatment of COPD? Hoogendoorn M; Kappelhoff BS; Overbeek JA; Wouters EF; Rutten-van Mölken MP Neth J Med; 2012 Oct; 70(8):357-64. PubMed ID: 23065983 [TBL] [Abstract][Full Text] [Related]
9. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). Friedman M; Menjoge SS; Anton SF; Kesten S Pharmacoeconomics; 2004; 22(11):741-9. PubMed ID: 15250751 [TBL] [Abstract][Full Text] [Related]
10. [Cost-effectiveness analysis of tiotropium compared to ipratropium and salmeterol]. García Ruiz AJ; Leiva Fernández F; Martos Crespo F Arch Bronconeumol; 2005 May; 41(5):242-8. PubMed ID: 15919004 [TBL] [Abstract][Full Text] [Related]
11. Using cost-effectiveness analysis to sharpen formulary decision-making: the example of tiotropium at the Veterans Affairs health care system. Onukwugha E; Mullins CD; DeLisle S Value Health; 2008; 11(5):980-8. PubMed ID: 18194405 [TBL] [Abstract][Full Text] [Related]
12. Tiotropium: a bronchodilator for chronic obstructive pulmonary disease. Somand H; Remington TL Ann Pharmacother; 2005 Sep; 39(9):1467-75. PubMed ID: 16030078 [TBL] [Abstract][Full Text] [Related]
13. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Oostenbrink JB; Rutten-van Mölken MP; Al MJ; Van Noord JA; Vincken W Eur Respir J; 2004 Feb; 23(2):241-9. PubMed ID: 14979498 [TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence. Mauskopf JA; Baker CL; Monz BU; Juniper MD J Med Econ; 2010; 13(3):403-17. PubMed ID: 20608887 [TBL] [Abstract][Full Text] [Related]
15. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD. Sun SX; Marynchenko M; Banerjee R; Cheng D; Mocarski M; Yin D; Yu AP; Wu EQ J Med Econ; 2011; 14(6):805-15. PubMed ID: 21992217 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial. Hoogendoorn M; Al MJ; Beeh KM; Bowles D; Graf von der Schulenburg JM; Lungershausen J; Monz BU; Schmidt H; Vogelmeier C; Rutten-van Mölken MP Eur Respir J; 2013 Mar; 41(3):556-64. PubMed ID: 22700844 [TBL] [Abstract][Full Text] [Related]
19. The association between inhaled long-acting bronchodilators and less in-hospital care in newly-diagnosed COPD patients. Kim J; Kim K; Kim Y; Yoo KH; Lee CK; Yoon HK; Kim YS; Park YB; Lee JH; Oh YM; Lee SD; Lee SW Respir Med; 2014 Jan; 108(1):153-61. PubMed ID: 23993445 [TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy. Zaniolo O; Iannazzo S; Pradelli L; Miravitlles M Eur J Health Econ; 2012 Feb; 13(1):71-80. PubMed ID: 21086017 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]